Objectives: This study sought to evaluate the feasibility and safety of autologous bone
marrow–derived and cardiogenically oriented mesenchymal stem cell therapy and to probe …

Aims Cardiopoietic cells, produced through cardiogenic conditioning of patients'
mesenchymal stem cells, have shown preliminary efficacy. The Congestive Heart Failure …

Aims Cardiopoiesis is a conditioning programme that aims to upgrade the
cardioregenerative aptitude of patient‐derived stem cells through lineage specification …

Rationale: Cell dose and concentration play crucial roles in phenotypic responses to cell-
based therapy for heart failure. Objective: To compare the safety and efficacy of 2 doses of …

Stem cell therapy aimed at restoring organ function, notably myocardial repair and
regeneration postmyocardial infarction (MI), is one of the most exciting and promising …

Importance Stem cell therapy is a promising treatment strategy for patients with heart failure,
which accounts for more than 10% of deaths in the United States annually. Despite more …

Cardiac cell therapy has now been in clinical use since 10years. Both autologous skeletal
myoblasts and bone marrow-derived different cell subsets (mononuclear cells …

Rationale: Autologous bone marrow mesenchymal stem cells (MSCs) and c-kit+ cardiac
progenitor cells (CPCs) are 2 promising cell types being evaluated for patients with heart …

Aims Left ventricular (LV) reverse remodelling is an important marker of improved outcomes
in patients with advanced heart failure (HF). We examined the impact of the intramyocardial …

This review summarizes the results of clinical trials of cell therapy in patients with heart
failure (HF). In contrast to acute myocardial infarction (where results have been consistently …